Silence Therapeutics plc (SLN)
Last Price$4.3(4.0%)
Market Cap$211.4B
SLN Rating
SLN Quality rating performance
SLN Intrinsic Value
Key Highlights:
As of Mar 03, 2025 SLN Relative Value is $0.0, which is overvalued by 99.7%, compared to current share price of $4.3.
As of Mar 03, 2025 SLN DCF Value is N/A, which is undervalued by N/A, compared to current share price of $4.3.
SLN Share Price History
1W (11.3%)
1M (14.6%)
6M (77.5%)
YTD (76.7%)
1Y (83.5%)
3Y (76.4%)
5Y (77.8%)
10Y (77.8%)
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
SLN Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$211.4B
$211.2B
£16.2M
(£43.9M)
Shares Outstanding
49B
Employees
N/A
Growth (CAGR)
166.0%
22.0%
(0.72%)
39.5%
(18.3%)
(64.14%)
Profitability
44.8%
(359.0%)
(362.3%)
(269.8%)
(270.5%)
68.6%
Intrinsic Value
$0.0 (99.8% overvalued)
N/A
$0.0
N/A
Valuation (LTM)
Return on Capital
Financial Health
(£128.9M)
2.9x
(6.0x)
Dividends
Earnings
Jan 01, 1970
MISS by 0.0%
MISS by 33.3%
320.0%
6 Beat & 4 Miss
SLN Stock Financials
SLN Income Statement Metrics
Annual
Quarterly
LTM
SLN Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
($48.9M) -13.4% YoY
Capital Expenditure (CAPEX)
($56.0K) -88.4% YoY
Free Cash Flow (FCF)
($49.0M) -14.2% YoY
SLN Income Statement Overview
Annual
Quarterly
LTM
Dec'14
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
SLN Balance Sheet Overview
Annual
Quarterly
LTM
Dec'14
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Assets
Liabilities
Total assets
$119.4M
Current assets ($103.1M, 86.4% of total)
$68.7M (57.6%)
$24.0M (20.1%)
Other current assets
$10.4M (8.7%)
Non-current assets ($16.3M, 13.6% of total)
$361.3K (0.3%)
$2,306.7K (1.9%)
$361.3K (0.3%)
Other non-current assets
$13.3M (11.1%)
Financial position
($68.4M)
Cash & Short-term
Investments
Total Debt
SLN Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
SLN Earnings Surprises
Crunching data... Almost there!
SLN Dividends
SLN Dividend Yield
Crunching data... Almost there!
SLN Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with SLN
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$211.4B | 5.6 | $0.0 99.8% overvalued | (83.5%) | £16.2M | (£43.9M) | (42.1%) | (270.5%) | 44.8% | (1,274.8%) | 0.1% | |
$402.0B | 6.7 | $60.0 32.9% overvalued | (29.6%) | DKK 290.4B | DKK 70.0B | 25.0% | 24.1% | 84.7% | 35.5% | 71.6% | |
$125.5B | 5.7 | $195.0 59.6% overvalued | 14.0% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$74.0B | 6.5 | $1,013.8 48.0% undervalued | (29.5%) | $14.2B | $3,597.2M | 8.3% | 25.3% | 86.7% | 25.0% | 5.7% | |
$38.1B | 5.8 | $109.1 82.5% overvalued | 59.5% | $2,258.9M | ($211.2M) | 127.3% | (9.4%) | 86.8% | (41.3%) | N/A | |
$31.3B | 5.2 | $93.6 61.6% overvalued | 62.3% | $2,248.2M | ($42.6M) | 23.0% | (1.9%) | 85.6% | (7.2%) | 1,931.9% | |
$27.1B | 6.3 | $165.8 48.6% undervalued | 24.9% | €3,040.1M | €985.3M | (54.1%) | 32.4% | 84.3% | (41.4%) | 1.3% | |
$14.8B | 5.6 | $46.7 33.6% overvalued | 17.6% | $4,241.2M | $235.2M | 14.8% | 5.5% | 92.3% | (12.7%) | 1.3% | |
$14.6B | 5.9 | $0.5 97.4% overvalued | 327.0% | $0.0 | ($142.1M) | N/A | N/A | N/A | (3,335.4%) | 1.9% | |
$14.0B | 7.7 | $427.2 37.8% undervalued | 35.5% | $2,877.4M | $1,080.6M | 23.6% | 37.6% | 89.2% | 65.4% | 4.7% | |
$1,846.9M | 5.4 | $2,805.1 1,137.3% undervalued | 39.9% | $3,316.8M | ($1,009.2M) | 50.5% | (30.4%) | 83.1% | (38.4%) | 32.1% |
FAQ
What is Silence Therapeutics plc (SLN) stock rating?
As of today, Silence Therapeutics plc has a stock rating of N/A (out of 10), which is considered Great.
is Silence Therapeutics plc (SLN) a good stock to buy?
As of today, Silence Therapeutics plc has a Great stock rating, which is N/A undervalued. According to Value Sense backtesting, stocks with similar profile tend to outperform the market by 12.8%.